

Editorial announcing PubMed indexing of *Degenerative Neurological and Neuromuscular Disease*

Thomas Müller

Department of Neurology, St. Joseph
Hospital Berlin-Weißensee, Berlin,
Germany

In my role as an EIC, I am proud and happy to announce that *Degenerative Neurological and Neuromuscular Disease* is now included in the PubMed database. This is a big step forward for the development of this journal and will hopefully generate more submissions and exposure for our authors.

Degenerative Neurological and Neuromuscular Disease is an open access journal that provides authors the ability to publish novel papers that can then be read by anyone with access to the Internet, and therefore increasing exposure and encouraging scientific discussions in the important field of chronic neurodegenerative and neuromuscular disorders.

From pharmaceutical advances, such as riluzole in the extension of median survival times in patients with amyotrophic lateral sclerosis,¹ to updated perspectives on biomarkers of Duchenne muscular dystrophy,² research published in *Degenerative Neurological and Neuromuscular Disease* has made a substantial difference in its field. Key papers of interest include “Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study”³ by Irish et al, which has the highest Altmetric score of the journal.

This journal welcomes the submission of reviews, case reports, study reports, novel post hoc analyses, and original research on all aspects of degenerative neurological and neuromuscular diseases, including the identification of therapeutic targets, pathophysiology, biomarker and cellular research, epidemiology, and the optimal use of preventative and integrated treatment interventions. All papers submitted to the journal undergo a rigorous and fast peer review process. I hope this journal’s approach will find further growing interest in the scientific community, as it continues to achieve its aim of increasing exposure of discussions and insights in the field.

I would like to thank everyone who has helped the journal achieve in the years since its launch in 2011, and we welcome your submissions.

Disclosure

The author reports no conflicts of interest in this work.

References

1. Hincheliff M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. *Degener Neurol Neuromuscul Dis*. 2018;7:61–70.
2. Al-Khalil Szgyarto C, Spitali P: biomarkers of Duchenne muscular dystrophy: current findings. *Degener Neurol Neuromuscul Dis*. 2017;8:1–13.
3. Irish AK, Erickson CM, Wahls TL, Snetselaar LG, Darling WG. Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study. *Degener Neurol Neuromuscul Dis*. 2016;7:1–18.

Correspondence: Thomas Müller
Department of Neurology, St. Joseph
Hospital Berlin-Weißensee, Gartenstraße
1, Berlin 13088, Germany
Email th.mueller@alexianer.de

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Degenerative Neurological and Neuromuscular Disease 'Editorial' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Degenerative Neurological and Neuromuscular Disease editors. While all reasonable steps have been taken to confirm the content of each Editorial, Dove Medical Press accepts no liability in respect of the content of any Editorial, nor is it responsible for the content and accuracy of any Editorial.

Degenerative Neurological and Neuromuscular Disease

Dovepress

Publish your work in this journal

Degenerative Neurological and Neuromuscular Disease is an international, peer-reviewed, open access journal focusing on research into degenerative neurological and neuromuscular disease, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced

survival and quality of life for the patient. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/degenerative-neurological-and-neuromuscular-disease-journal>